Alloy Therapeutics Collaborates with Pfizer for New Antibody Discovery Platform

Alloy Therapeutics Inc., a biotechnology ecosystem company focused on expanding access to advanced drug discovery technologies, announced a new strategic collaboration with Pfizer Inc. to develop a platform aimed at improving the discovery of potent and highly specific antibodies for challenging targets.

“Pfizer has leveraged our industry-leading ATX-GxTM platform for several years, and we collaborated closely with them to develop the common light chain ATX-CLC strains. This collaboration exemplifies how pharma can leverage Alloy’s technology and expertise broadly in antibody discovery and technological innovation by participating in the creation of pre-competitive tools,” said Heather Schwoebel, Chief Business Officer, Antibodies and Head of Strategic Collaborations at Alloy.

Learn more